Photo by cdc from unsplash
Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior… Click to show full abstract
Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improving clinical outcomes in heart failure patients, but whether this additional benefit exists in reversing atrial remodelling and reducing AF recurrence of RFCA‐treated AF patients remains uncovered.
Keywords:
sacubitril valsartan;
valsartan attenuates;
attenuates atrial;
atrial structural;
atrial fibrillation
Journal Title: ESC Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESC Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!